Lung Cancer
Conditions
Keywords
AT-101, erlotinib, Unresectable Stage IIIB, 09-026
Brief summary
Advanced stage lung cancer is generally treated with anti-cancer medication called chemotherapy. Most lung cancer is caused by cigarette smoking. However, some lung cancers develop in people who never smoked or who only smoked for a short period of time. This type of lung cancer may respond to a medication called erlotinib (Tarceva). Erlotinib is an anticancer pill that is approved by the Food and Drug Administration (FDA) for use in patients with advanced lung cancer. Unfortunately, erlotinib does not work for all patients or only works for a period of time. The doctors are trying to find ways to improve the effect of erlotinib by combining it with another anti-cancer medication. Ascenta Therapeutics, Inc. has developed a drug called AT-101 as a potential treatment for cancer. AT-101 is an investigational drug. That means that AT-101 is not approved by the United States Food and Drug Administration (FDA) for general use. The FDA does permit its use in studies like this one to determine whether it is safe and effective. This is the first study to examine the effects of AT-101 and erlotinib. It is hoped that by combining AT-101 with erlotinib, AT-101 may help erlotinib work better to shrink lung cancer. Studies that have been performed in the laboratory suggest that AT-101 in combination with erlotinib may be more effective at shrinking tumors than erlotinib alone.
Interventions
DRUGoral erlotinib and pulsed doses of oral AT-101
Patients will receive oral erlotinib 100 mg daily and pulsed doses of oral AT-101 given 40 mg twice daily on days 1-3 of a 21-day cycle. If the initial combination of erlotinib and AT-101 is tolerated, dose escalation of erlotinib to 150 mg daily will be allowed at the discretion of the treating investigator at the start of cycle 2. Patients will continue receiving treatment on study until they refuse further therapy, develop evidence of progressive disease, or develop unacceptable toxicity or a medical condition that would, in the judgment of the investigator,
Sponsors
Ascenta Therapeutics
Memorial Sloan Kettering Cancer Center
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Ability to understand and the willingness to sign a written informed consent form; the consent form must be signed by the patient prior to any study-specific procedures. * Patients age ≥ 18 years with histologically confirmed wet Stage IIIB (with malignant pleural effusion) or Stage IV non-small cell lung cancer (metastatic or recurrent). * Pathologic confirmation of non-small cell lung cancer at Memorial Sloan-Kettering Cancer Center. * Presence of exon 19 or exon 21 EGFR activating mutation. * No prior EGFR tyrosine kinase therapy. * No prior systemic therapy for advanced NSCLC (Stage IIIB with malignant effusion or Stage IV) * Karnofsky performance status \> or = to 70% OR ECOG performance status ≤ 2. * Measurable disease defined as greater than or equal to one known/suspected malignant lesion \> or = to 1 cm measurable in two dimensions. * Adequate hematologic, renal, and/or hepatic function: WBC \> or = to 3,000/ul, hemoglobin \> or = to 9.0 g/dl, platelet count \> or = to 100,000/ul, total bilirubin ≤ 1.5 X UNL, AST ≤ 2.5 X UNL, and serum creatinine within 1.5 x the upper limit of normal (\<1.95 at MSKCC) or calculated creatinine clearance \> or = to 60 ml/min. * Able to swallow and retain oral medication. * Willingness and ability to comply with study procedures and follow-up examination. * Four weeks since any major surgery, completion of radiation, or completion of all prior chemotherapy. * Acute toxicities of any prior therapy must have resolved to \< Grade 1 or baseline prior to starting study therapy. * Effective contraception.
Exclusion criteria
* Prior treatment with gefitinib, erlotinib, or other EGFR tyrosine kinase inhibitor therapy. * Concurrent cytotoxic or biological therapy. * Known KRAS mutation. * History within the past 6 months of myocardial infarction, cardiac stent placement, or intermittent ischemia with troponin leak. * Active secondary malignancy or history of other malignancy within the last 3 years except non-melanoma skin cancer and in-situ carcinoma of the cervix. * Active, serious comorbid medical conditions including severe infection, malnutrition, unstable angina, congestive heart failure (New York Heart Association Class III or IV), pulmonary fibrosis, or condition that would be felt by treating physician to preclude safe participation in the clinical trial. * Patients with malabsorption syndrome or diseases significantly affecting the gastrointestinal tract including prior gastric resection or small bowel resection, inflammatory bowel disease, or partial or complete small bowel obstruction. * Unstable brain or leptomeningeal metastases including patients who continue to require glucocorticoids for brain or leptomeningeal metastases. * Women who are pregnant or breast-feeding. * Inability/unwillingness to comply with protocol treatment or follow-up.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Radiographic Objective Response Rate | 21 days after cycle one | (CR+PR, by WHO Criteria for Standard Bidimensional Tumor Measurement) After One 21-day Cycle of Combination Therapy With Erlotinib and AT-101 |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Oral Erlotinib and Pulsed Doses of Oral AT-101 Treatment-naïve advanced (Wet Stage IIIB and IV)NSCLC patients with EGFR activating mutations. | 6 |
| Total | 6 |
Withdrawals & dropouts
| Period | Reason | FG000 |
|---|---|---|
| Overall Study | Withdrawal by Subject | 1 |
Baseline characteristics
| Characteristic | Oral Erlotinib and Pulsed Doses of Oral AT-101 |
|---|---|
| Age, Categorical <=18 years | 0 Participants |
| Age, Categorical >=65 years | 2 Participants |
| Age, Categorical Between 18 and 65 years | 4 Participants |
| Sex: Female, Male Female | 5 Participants |
| Sex: Female, Male Male | 1 Participants |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | — / — |
| other Total, other adverse events | 5 / 5 |
| serious Total, serious adverse events | 1 / 5 |
Outcome results
Primary
Radiographic Objective Response Rate
(CR+PR, by WHO Criteria for Standard Bidimensional Tumor Measurement) After One 21-day Cycle of Combination Therapy With Erlotinib and AT-101
Time frame: 21 days after cycle one
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Oral Erlotinib and Pulsed Doses of Oral AT-101 | Radiographic Objective Response Rate | Stable Disease (SD) | 3 participants |
| Oral Erlotinib and Pulsed Doses of Oral AT-101 | Radiographic Objective Response Rate | Minor Response (MR) | 1 participants |
| Oral Erlotinib and Pulsed Doses of Oral AT-101 | Radiographic Objective Response Rate | Partial Response (PR) | 1 participants |